Target intelligence / Profile preview

Endoplasmic reticulum alpha-glucosidase I

Molecular classification
Enzyme, Glycoside hydrolase
01

Overview

Endoplasmic reticulum (ER) alpha-glucosidase I is an essential enzyme located in the lumen of the endoplasmic reticulum. It catalyzes the initial trimming step by removing the outermost α-1,2-linked glucose residue from Glc₃Man₉GlcNAc₂ oligosaccharides attached to nascent glycoproteins. This action is followed by further glucose removal by ER alpha-glucosidase II. The sequential trimming facilitates binding to chaperones such as calnexin and calreticulin, which are crucial for correct protein folding and quality control within the ER. Properly folded proteins are then transported to the Golgi apparatus for further processing; misfolded proteins may be retained in the ER or targeted for degradation via ER-associated degradation (ERAD). Inhibition of ER alpha-glucosidases disrupts viral envelope glycoprotein maturation, impairing morphogenesis and infectivity of many enveloped viruses including hepatitis C virus (HCV), dengue virus, influenza virus, flaviviruses, and filoviruses. The gene encoding this enzyme is essential: knockout or severe mutation impairs quality control mechanisms within cells leading to accumulation of misfolded proteins and potential cell stress responses or disease phenotypes.

02

Mechanism of action

Inhibition of ER alpha-glucosidase I disrupts viral envelope glycoprotein maturation, impairing morphogenesis and infectivity of many enveloped viruses. Selective inhibition can be achieved with specific iminosugars that mimic substrate structure.

03

Biological functions

Protein N-glycosylationProtein foldingQuality controlGlycoprotein maturation
04

Disease associations

InfectionCongenital disorders related to protein misfolding
05

Safety considerations

Potential cell stress responses due to accumulation of misfolded proteins.Genetic defects leading to loss-of-function mutations can cause rare congenital disorders related to protein misfolding.
06

Interacting drugs

1-deoxynojirimycin (DNJ) derivatives

1 more in the full profile.

07

Biomarkers

Triglucosylated glycans

Beyond the preview

Go deeper on Endoplasmic reticulum alpha-glucosidase I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endoplasmic reticulum alpha-glucosidase I.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call